Cargando…
Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.
Plasminogen activator (PA) is a serine protease existing in two forms known as tissue-type (t-PA) and urokinase-type (u-PA). To examine whether PA is related to the postoperative clinical course of human breast cancer, total PA activity, t-PA activity, u-PA activity, and immunoreactive t-PA were det...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968379/ https://www.ncbi.nlm.nih.gov/pubmed/8394731 |
_version_ | 1782134727529988096 |
---|---|
author | Yamashita, J. Ogawa, M. Yamashita, S. Nakashima, Y. Saishoji, T. Nomura, K. Inada, K. Kawano, I. |
author_facet | Yamashita, J. Ogawa, M. Yamashita, S. Nakashima, Y. Saishoji, T. Nomura, K. Inada, K. Kawano, I. |
author_sort | Yamashita, J. |
collection | PubMed |
description | Plasminogen activator (PA) is a serine protease existing in two forms known as tissue-type (t-PA) and urokinase-type (u-PA). To examine whether PA is related to the postoperative clinical course of human breast cancer, total PA activity, t-PA activity, u-PA activity, and immunoreactive t-PA were determined in tissue extracts from 144 breast cancer specimens. The patients were initially divided into four groups according to the postoperative clinical course: Group I (83 patients who are disease-free), Group II (20 patients whose first metastases were found only in bone), Group III (19 patients whose first metastases were found in both bone and lung), and Group IV (22 patients whose first metastases were found only in lung). Total PA activity was significantly lower in Groups, II, III and IV than in Group I. Both t-PA activity and t-PA antigen levels were also significantly lower in Groups II, III and IV than in Group I, while no significant difference was found in u-PA activity among these groups, indicating that low activity of total PA in Groups II, III and IV was due to a decrease in t-PA but not in u-PA. In the multivariate analyses, t-PA activity was found to be an independent prognostic factor for relapse-free survival. When four groups of patients were further analysed in terms of nodal status, both t-PA activity and antigen levels were markedly decreased in the node-negative Group II compared with the node-negative Groups III and IV or with the node-positive Groups II, III and IV. Of additional interest, u-PA activity was significantly higher in node-positive patients than in node-negative patients with any group. The clinico-pathologic analyses of the patients in this series showed that node involvement and lymphatic invasion were more frequently positive in Groups III and IV than in Groups I and II. When 144 breast cancers were categorised in terms of combinations of oestrogen receptor (ER) and progesterone receptor (PgR) status, breast cancers which were positive for both receptors were found to contain the highest t-PA activity and antigen. This study provides provocative evidence suggesting a possible differential significance of t-PA and u-PA expression in human breast cancer. |
format | Text |
id | pubmed-1968379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1993 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19683792009-09-10 Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Yamashita, J. Ogawa, M. Yamashita, S. Nakashima, Y. Saishoji, T. Nomura, K. Inada, K. Kawano, I. Br J Cancer Research Article Plasminogen activator (PA) is a serine protease existing in two forms known as tissue-type (t-PA) and urokinase-type (u-PA). To examine whether PA is related to the postoperative clinical course of human breast cancer, total PA activity, t-PA activity, u-PA activity, and immunoreactive t-PA were determined in tissue extracts from 144 breast cancer specimens. The patients were initially divided into four groups according to the postoperative clinical course: Group I (83 patients who are disease-free), Group II (20 patients whose first metastases were found only in bone), Group III (19 patients whose first metastases were found in both bone and lung), and Group IV (22 patients whose first metastases were found only in lung). Total PA activity was significantly lower in Groups, II, III and IV than in Group I. Both t-PA activity and t-PA antigen levels were also significantly lower in Groups II, III and IV than in Group I, while no significant difference was found in u-PA activity among these groups, indicating that low activity of total PA in Groups II, III and IV was due to a decrease in t-PA but not in u-PA. In the multivariate analyses, t-PA activity was found to be an independent prognostic factor for relapse-free survival. When four groups of patients were further analysed in terms of nodal status, both t-PA activity and antigen levels were markedly decreased in the node-negative Group II compared with the node-negative Groups III and IV or with the node-positive Groups II, III and IV. Of additional interest, u-PA activity was significantly higher in node-positive patients than in node-negative patients with any group. The clinico-pathologic analyses of the patients in this series showed that node involvement and lymphatic invasion were more frequently positive in Groups III and IV than in Groups I and II. When 144 breast cancers were categorised in terms of combinations of oestrogen receptor (ER) and progesterone receptor (PgR) status, breast cancers which were positive for both receptors were found to contain the highest t-PA activity and antigen. This study provides provocative evidence suggesting a possible differential significance of t-PA and u-PA expression in human breast cancer. Nature Publishing Group 1993-09 /pmc/articles/PMC1968379/ /pubmed/8394731 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Yamashita, J. Ogawa, M. Yamashita, S. Nakashima, Y. Saishoji, T. Nomura, K. Inada, K. Kawano, I. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. |
title | Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. |
title_full | Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. |
title_fullStr | Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. |
title_full_unstemmed | Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. |
title_short | Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. |
title_sort | differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968379/ https://www.ncbi.nlm.nih.gov/pubmed/8394731 |
work_keys_str_mv | AT yamashitaj differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer AT ogawam differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer AT yamashitas differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer AT nakashimay differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer AT saishojit differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer AT nomurak differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer AT inadak differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer AT kawanoi differentialbiologicalsignificanceoftissuetypeandurokinasetypeplasminogenactivatorinhumanbreastcancer |